Cancers that were once considered incurable now have new treatment options. Among these innovations are CAR-T (chimeric ...

CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies.

In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy blood-forming cells. If the disease recurs after treatment or fails to respond, CAR ...

Add Yahoo as a preferred source to see more of our stories on Google. Shirley Powers undergoes treatment for her chronic lymphocytic leukemia. It took almost a decade of treatment including a CAR ...

T-cell therapy has transformed the treatment landscape for patients with relapsed or refractory large B-cell lymphoma (LBCL), ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...

Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...

In addition to scalability, another opportunity is presented by clinical feasibility and performance. For example, lymphodepletion conditioning, which is a must for ex vivo-engineered CAR-T cells, is ...

CAR T-cell therapy has revolutionized treatment for many blood cancers. However, the benefits of its use in the early stages of care remain uncertain. Chimeric antigen receptor (CAR) T-cell therapy ...